Latest Insider Transactions at Brainstorm Cell Therapeutics Inc. (BCLI)
This section provides a real-time view of insider transactions for Brainstorm Cell Therapeutics Inc. (BCLI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BRAINSTORM CELL THERAPEUTICS INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BRAINSTORM CELL THERAPEUTICS INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Oct 01
2024
|
Chaim Lebovits President & CEO |
BUY
Open market or private purchase
|
Direct |
1,836
+2.22%
|
$5,508
$3.43 P/Share
|
|
Sep 30
2024
|
Chaim Lebovits President & CEO |
BUY
Open market or private purchase
|
Direct |
22,000
+1.82%
|
$0
$0.23 P/Share
|
|
Jul 19
2024
|
Ibrahim B. Dagher Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
63,000
-100.0%
|
$0
$0.35 P/Share
|
|
Jun 24
2024
|
Hartoun Hartounian EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+50.0%
|
-
|
|
May 28
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+1.27%
|
$0
$0.52 P/Share
|
|
May 22
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+2.13%
|
$0
$0.64 P/Share
|
|
May 21
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+2.17%
|
$0
$0.58 P/Share
|
|
May 13
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+0.9%
|
$0
$0.49 P/Share
|
|
May 11
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+0.91%
|
$0
$0.47 P/Share
|
|
May 10
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+1.82%
|
$0
$0.46 P/Share
|
|
May 07
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
66,300
+5.89%
|
$0
$0.37 P/Share
|
|
May 06
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+11.96%
|
$0
$0.38 P/Share
|
|
Apr 19
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+1.72%
|
$0
$0.52 P/Share
|
|
Apr 18
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
115,072
+12.0%
|
$0
$0.53 P/Share
|
|
Apr 17
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+15.14%
|
$0
$0.55 P/Share
|
|
Mar 11
2024
|
Alla Patlis Officer |
BUY
Grant, award, or other acquisition
|
Direct |
65,246
+50.0%
|
-
|
|
Mar 11
2024
|
Uri Yablonka EVP & Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
109,426
+46.29%
|
-
|
|
Mar 11
2024
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
241,935
+36.36%
|
-
|
|
Mar 11
2024
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
305,198
+33.77%
|
-
|
|
Sep 01
2023
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
11,500
+5.96%
|
$11,500
$1.77 P/Share
|
|
Aug 02
2023
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+17.07%
|
-
|
|
Aug 02
2023
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,185
+9.61%
|
-
|
|
Jun 19
2023
|
Nir Naor Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,999
+50.0%
|
-
|
|
May 01
2023
|
Kirk Taylor Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Apr 20
2023
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+35.71%
|
-
|
|
Apr 20
2023
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+22.25%
|
-
|
|
Dec 07
2022
|
Stacy Lindborg Co-Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+36.84%
|
-
|
|
Sep 18
2022
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,185
+14.29%
|
-
|
|
Mar 06
2022
|
Ralph Dr. Kern COO and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,885
+13.84%
|
-
|
|
Feb 01
2022
|
Anthony J. Polverino Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,882
+13.01%
|
-
|
|
Dec 15
2021
|
June Sherie Almenoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+25.0%
|
-
|
|
Dec 15
2021
|
Anthony J. Polverino Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+8.31%
|
-
|
|
Dec 15
2021
|
Malcolm S Taub Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+13.43%
|
-
|
|
Dec 10
2021
|
June Sherie Almenoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,000
+33.33%
|
-
|
|
Dec 10
2021
|
Sankesh Abbhi Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,666
+37.06%
|
-
|
|
Dec 10
2021
|
Anthony J. Polverino Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,216
+9.99%
|
-
|
|
Dec 10
2021
|
Malcolm S Taub Director |
BUY
Grant, award, or other acquisition
|
Direct |
12,000
+15.52%
|
-
|
|
Dec 10
2021
|
Chaim Lebovits President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
31,185
+16.67%
|
-
|
|
Dec 10
2021
|
Ralph Dr. Kern COO and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,885
+16.07%
|
-
|
|
Dec 30
2020
|
Preetam Shah EVP, CFO and Treasurer |
SELL
Payment of exercise price or tax liability
|
Direct |
25,000
-68.31%
|
$100,000
$4.64 P/Share
|